Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1674
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17992369 | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody | Final Rejection | Janssen Biotech, Inc. |
| 18015444 | METHODS FOR TREATING CARDIOVASCULAR DISEASE | Final Rejection | Novo Nordisk A/S |
| 18174889 | METHODS FOR PRODUCING ANTIBODIES | Non-Final OA | Genentech, Inc. |
| 18031840 | CD47 BLOCKADE AND COMBINATION THERAPIES THEREOF FOR REDUCTION OF VASCULAR INFLAMMATION | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18674399 | METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18252005 | METHODS AND SYSTEMS FOR CLASSIFICATION AND TREATMENT OF SMALL CELL LUNG CANCER | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18187242 | USE OF CANAKINUMAB | Non-Final OA | Novartis AG |
| 18283887 | METHODS AND MATERIALS FOR TARGETING TUMOR ANTIGENS | Non-Final OA | The Johns Hopkins University |
| 18033746 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH TGF-BETA ACTIVITY | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 18546199 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | Non-Final OA | Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
| 17791194 | TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Non-Final OA | Apellis Pharmaceuticals, Inc. |
| 18254468 | Superior Neutralization of SARS-CoV-2 by Deglycosylated Human Angiotensin Converting Enzyme 2 (ACE2) | Non-Final OA | IMBA - Institut für Molekulare Biotechnologie GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy